Wide Ranks

MRSN

Mersana Therapeutics, Inc.

2.19

Top Statistics
Market Cap 270 M Forward PE -3.34 Revenue Growth 63.70 %
Current Ratio 0.00 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins -214.20 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months 7.77
Profitability
Profit Margins -214.20 % Operating Margins -95.80 %
Balance Sheet
Total Cash Total Cash Per Share Total Debt
Total Debt To Equity 390.80 Current Ratio 0.00 Book Value Per Share 0.3060
All Measures
Short Ratio 936.00 % Message Board Id finmb_1623526 Shares Short Prior Month 9 M
City Cambridge Uuid f2bdb9ce-4a35-377e-aaea-f82800954196 Previous Close 2.17
First Trade Date Epoch Utc 1 B Book Value 0.3060 Volume 608649
Price To Book 7.16 Fifty Two Week Low 1.22 Total Revenue 34 M
Shares Short Previous Month Date 1 B Target Median Price 7.00 Max Age 86400
Recommendation Mean 1.40 Sand P52 Week Change 0.3133 Operating Margins -95.80 %
Target Mean Price 6.50 Net Income To Common -74619000 Short Percent Of Float 0.1000
Implied Shares Outstanding 123 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 1 M Average Volume10days 1 M Next Fiscal Year End 1 B
Revenue Per Share 0.2860 Held Percent Insiders 0.0126 Ebitda Margins -223.32 %
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Regular Market Previous Close 2.17 Target Low Price 3.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 2.07 Open 2.18 Dividend Yield 0.00 %
State MA Time Zone Short Name EST Trailing Eps -0.6000
Day Low 2.11 Address1 840 Memorial Drive Shares Outstanding 123 M
Price Hint 4 Target High Price 9.00 Website https://www.mersana.com
52 Week Change 0.3273 Average Volume 1 M Forward Eps -0.7000
Recommendation Key strong_buy Compensation As Of Epoch Date 1 B Is_sp_500 False
Regular Market Day High 2.23 Profit Margins -214.20 % Debt To Equity 390.80
Fifty Two Week High 6.28 Day High 2.23 Shares Short 9 M
Regular Market Open 2.18 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 63.70 % Shares Percent Shares Out 0.0762 Currency USD
Time Zone Full Name America/New_York Market Cap 270 M Is_nasdaq_100 False
Zip 02139 Quote Type EQUITY Industry Biotechnology
Long Name Mersana Therapeutics, Inc. Regular Market Day Low 2.11 Held Percent Institutions 0.9536
Current Price 2.19 Financial Currency USD Current Ratio 0.00
Industry Disp Biotechnology Number Of Analyst Opinions 8 Country United States
Float Shares 71 M Two Hundred Day Average 2.66 Price To Sales Trailing12 Months 7.77
Forward PE -3.34 Regular Market Volume 608649 Ebitda -77797000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs.

The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC.

It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.

A.

, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.

The company was formerly known as Nanopharma Corp.

and changed its name to Mersana Therapeutics, Inc. in November 2005.

Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.